Business Wire

Celltrion Celebrates a Decade of Biosimilar Innovation in Europe


Celltrion Healthcare today launches a campaign to celebrate a decade of continuous biosimilar innovation in Europe. The campaign coincides with 10 years since the world’s first monoclonal antibody biosimilar infliximab, Remsima®, received regulatory approval from the European Medicines Agency (EMA).

Biosimilars have been pivotal in driving treatment advancements in immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Thousands of patients in Europe and globally have benefitted from biosimilars since their initial approval, incurring both patient health and economic benefits.1

In the previous decade, there has been an ongoing pursuit to continue improving treatments and maximising patient quality of life. This sustained innovation and evolution of biosimilars has delivered benefits beyond their reference product. The development of new administration methods has ushered in a new era, offering patients a more convenient and accessible treatment options which can be administered at home.

Alongside the wide-ranging patient benefits, biosimilars have delivered savings to economies and healthcare systems across the world. Several analyses have found that use of biosimilars in place of their reference product in Europe could save hundreds of millions of Euros. For instance, the use of infliximab biosimilar had saved approximately £100 million in a year in the United Kingdom alone, according to the announcement made by United Kingdom’s National Health Service (NHS).2

Taehun Ha, Senior Vice President and Head of Europe Division at Celltrion Healthcare, said, “We are proud to recognise the tremendous impact that biosimilars have had on patients in Europe. Efforts to make high-quality biologics more affordable have paved the way for the widespread adoption of biosimilars across the continent and supported in improving patient outcomes. We at Celltrion remain committed to creating innovative treatments that prioritise the needs of patients and expand their treatment options.”

Professor Laurent Peyrin-Biroulet, Head of the Inflammatory Bowel Disease (IBD) group at the Gastroenterology Department of the University Hospital of Nancy, France,said, “Initially, we were intrigued by the arrival of biosimilars, especially with the first pivotal studies focusing solely on rheumatology. However, it became clear biosimilars offered a promising opportunity to reduce healthcare costs and improve the management of multiple diseases. Studies such as PLANETCD and NORSWITCH have added to the extensive evidence of their efficacy and safety, quickly reassuring us, in addition to our real-life experience. Biosimilars made it possible to reduce treatment prices - it was an economic revolution for patients and healthcare systems.”

In celebration of a decade of innovation and commitment to IMID treatment landscape, Celltrion is launching an innovative campaign across Europe. The campaign aims to highlight the positive impact of biosimilars to patients and healthcare systems, whilst reflecting on what the future could hold through continued innovation. Activities will include a global speaker tour, presentations by KOLs showcasing the latest clinical data, a report highlighting a decade of innovation and a celebration at United European Gastroenterology Week (UEGW) 2023 in Copenhagen.

Notes to Editors:

About the Campaign

This initiative aims to highlight the impact of infliximab biosimilars to patients and healthcare system in Europe over the last decade and spark discussion on the future of biosimilars and what can be achieved through harnessing the power of continued innovation. The campaign coincides with the 10th year since the approval of Remsima® in Europe.

About Biosimilars

A biosimilar is a biologic product developed and proven to be biologically identical to a previously approved biologic known as the reference product using the same active substances. Known for its high quality and affordability, the biosimilar has become an innovative medicine for patients with different diseases across the world including Europe.

About Remsima®

Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. Remsima® has continued expanding globally since its introduction in Europe in 2013 and has been authorised in over 100 countries worldwide as of January 2023, with a 55% market share in Europe in 2022.3

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries.

Celltrion is committed to delivering affordable biologics and addressing healthcare needs, delivering innovations in treatments for patients with IMID, such as advances in treatment administration that enable people to access at-home treatment, allowing people to have an improved quality of life whilst managing their condition.

For more information, please visit:


1 Jahnsen J., Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therap Adv Gastroenterol. 2016 May;9(3):322-9. doi: 10.1177/1756283X16636764. Epub 2016 Mar 21. PMID: 27134662; PMCID: PMC4830106.
2 NHS (National Health Service). The NHS saves £324 million in a year by switching to better value medicines. Available at:
3 Celltrion, Inc. Fourth-Quarter and Full Year 2022 Earnings Release.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Holly Barber
+44 (0) 7759 301620

Tom Walden
+44 (0) 7423 534197

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 19:43:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an

Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 16:30:00 CEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 15:15:00 CEST | Press release

GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with

Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 13:53:00 CEST | Press release

Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 13:00:00 CEST | Press release

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas